within subject standard deviation in fully replicate design if carry over effect is present [General Sta­tis­tics]

posted by dshah  – India/United Kingdom, 2023-06-14 11:26 (260 d 12:41 ago) – Posting: # 23588
Views: 870

Hello Ankit!

❝ Cmax is due to the burst phase of release from the formulation however the plasma concentration required to produce therapeutic effect is very low i.e. < 5 % of Cmax and it remains in therapeutic range from Day 4 to 120 due to slow release of the product. It provides therapeutic effect for 4 months and then new injection has to be taken on day 120.

This seems to be LAI and from initial post also a HVD?

If by day 4- conc. are LT 5% of Cmax- then what is your half life? Why do you want to measure it for 120 days and the burst release doesn't have any toxicity impact? If even product name can not be shared- then it is difficult to be answered from very few details.


Complete thread:

UA Flag
 Admin contact
22,916 posts in 4,807 threads, 1,645 registered users;
33 visitors (0 registered, 33 guests [including 12 identified bots]).
Forum time: 23:07 CET (Europe/Vienna)

Nothing shocks me. I’m a scientist.    Harrison Ford (as Indiana Jones)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz